UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 58

Sortiert nach

Changes in expression of PD-L1 on peripheral T cells in patients with melanoma and lung cancer treated with PD-1 inhibitors

Scientific reports, 2021-07, Vol.11 (1), p.15312-11, Article 15312

2021

Link zum Volltext

Verfügbarkeit prüfen

Dabrafenib and trametinib treatment-associated fevers in metastatic melanoma causing extreme elevation in procalcitonin in the absence of infection

Anti-cancer drugs, 2018-09, Vol.29 (8), p.802-805

2018

Link zum Volltext

Verfügbarkeit prüfen

Tumour PD-L1 Expression in Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis

Cells (Basel, Switzerland), 2020-10, Vol.9 (11), p.2393

2020

Link zum Volltext

Verfügbarkeit prüfen

Prognostic value of HLA-I homozygosity in patients with non-small cell lung cancer treated with single agent immunotherapy

Journal for immunotherapy of cancer, 2020-11, Vol.8 (2), p.e001620

2020

Link zum Volltext

Verfügbarkeit prüfen

Activity of trametinib in K601E and L597Q BRAF mutation-positive metastatic melanoma

Melanoma research, 2014-10, Vol.24 (5), p.504-508

2014

Link zum Volltext

Verfügbarkeit prüfen

Resistant hypercalcaemia in metastatic parathyroid carcinoma

Medical journal of Australia, 2013-06, Vol.198 (10), p.559-561

2013

Link zum Volltext

Verfügbarkeit prüfen

FOXP3+ T regulatory lymphocytes in primary melanoma are associated with BRAF mutation but not with response to BRAF inhibitor

Pathology, 2015-10, Vol.47 (6), p.557-563

2015

Link zum Volltext

Verfügbarkeit prüfen

The role of oncology nurse practitioners in current oncology practice and lessons for Australia

Medical journal of Australia, 2014-04, Vol.200 (7), p.382-384

2014

Link zum Volltext

Verfügbarkeit prüfen

Association between Physical Activity and Reduced Mortality in Inoperable Lung Cancer

Journal of clinical medicine, 2023-11, Vol.12 (23), p.7346

2023

Link zum Volltext

Verfügbarkeit prüfen

High response rate with extended dosing of cemiplimab in advanced cutaneous squamous cell carcinoma

Journal for immunotherapy of cancer, 2024-03, Vol.12 (3), p.e008325

2024

Link zum Volltext

Verfügbarkeit prüfen

LOREALAUS: LOrlatinib REAL-World AUStralian Experience in Advanced ALK-Rearranged NSCLC

JTO clinical and research reports, 2023-04, Vol.4 (4), p.100490-100490, Article 100490

2023

Link zum Volltext

Verfügbarkeit prüfen

Sedentary Behaviour, Physical Activity, and Their Associations with Health Outcomes at the Time of Diagnosis in People with Inoperable Lung Cancer

Journal of clinical medicine, 2022-10, Vol.11 (19), p.5870

2022

Link zum Volltext

Verfügbarkeit prüfen

547 CERPASS: A randomized, controlled, open-label, phase 2 study of cemiplimab ± RP1 in patients with advanced cutaneous squamous cell carcinoma

Journal for immunotherapy of cancer, 2021-11, Vol.9 (Suppl 2), p.A577-A577

2021

Link zum Volltext

Verfügbarkeit prüfen

The place of PD-1 inhibitors in melanoma management

The lancet oncology, 2015-08, Vol.16 (8), p.873-874

2015

Link zum Volltext

Verfügbarkeit prüfen

Human leucocyte antigen genotype association with the development of immune-related adverse events in patients with non-small cell lung cancer treated with single agent immunotherapy

European journal of cancer (1990), 2022-09, Vol.172, p.98-106

2022

Link zum Volltext

Verfügbarkeit prüfen

Optimal management of immune-related toxicities associated with checkpoint inhibitors in lung cancer

Lung cancer (Amsterdam, Netherlands), 2015-05, Vol.88 (2), p.117-123

2015

Link zum Volltext

Verfügbarkeit prüfen

Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation

The New England journal of medicine, 2023-08, Vol.389 (8), p.710-721

2023

Link zum Volltext

Verfügbarkeit prüfen

Abstract P066: Prognostic and predictive value of pre-treatment T-Cell receptors (TCR) repertoire in non-small cell lung cancer (NSCLC) patients treated with single agent immunotherapy

Cancer immunology research, 2022-01, Vol.10 (1_Supplement), p.P066-P066

2022

Link zum Volltext

Verfügbarkeit prüfen

Circulating Melanoma Cell Subpopulations: Their Heterogeneity and Differential Responses to Treatment

Journal of investigative dermatology, 2015-08, Vol.135 (8), p.2040-2048

2015

Link zum Volltext

Verfügbarkeit prüfen

Clinical evidence for synergy between immunotherapy and radiotherapy (SITAR)

Journal of medical imaging and radiation oncology, 2022-09, Vol.66 (6), p.881-895

2022

Link zum Volltext

Verfügbarkeit prüfen

Phase Ib study of olinvacimab (O) with pembrolizumab (P) in patients with recurrent glioblastoma (rGBM)

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.e14545-e14545

2020

Link zum Volltext

Verfügbarkeit prüfen

Powering single-cell genomics to unravel circulating tumour cell subpopulations in non-small cell lung cancer patients

Journal of cancer research and clinical oncology, 2023-05, Vol.149 (5), p.1941-1950

2023

Link zum Volltext

Verfügbarkeit prüfen

Immune checkpoint inhibitor therapy for advanced cutaneous squamous cell carcinoma in Australia: a retrospective real world cohort study

Medical journal of Australia, 2024-02, Vol.220 (2), p.80-90

2024

Link zum Volltext

Verfügbarkeit prüfen

Brief Report: Real-World Toxicity and Survival of Combination Immunotherapy in Pleural Mesothelioma—RIOMeso

Journal of thoracic oncology, 2024-04, Vol.19 (4), p.636-642

2024

Link zum Volltext

Verfügbarkeit prüfen

Completion of Pembrolizumab in Advanced Non-Small Cell Lung Cancer—Real World Outcomes After Two Years of Therapy (COPILOT)

Clinical lung cancer, 2024-04

2024

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 58

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(54)
Mit Volltextzugriff
(56)

Publikationsform

Artikel
(56)
Berichte
(2)

Sprache

Englisch
(58)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Changes in expression of PD-L1 on peripheral T cells in patients with melanoma and lung cancer treated with PD-1 inhibitors

Dabrafenib and trametinib treatment-associated fevers in metastatic melanoma causing extreme elevation in procalcitonin in the absence of infection

Tumour PD-L1 Expression in Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis

Prognostic value of HLA-I homozygosity in patients with non-small cell lung cancer treated with single agent immunotherapy

Activity of trametinib in K601E and L597Q BRAF mutation-positive metastatic melanoma

Resistant hypercalcaemia in metastatic parathyroid carcinoma

FOXP3+ T regulatory lymphocytes in primary melanoma are associated with BRAF mutation but not with response to BRAF inhibitor

The role of oncology nurse practitioners in current oncology practice and lessons for Australia

Association between Physical Activity and Reduced Mortality in Inoperable Lung Cancer

High response rate with extended dosing of cemiplimab in advanced cutaneous squamous cell carcinoma

LOREALAUS: LOrlatinib REAL-World AUStralian Experience in Advanced ALK-Rearranged NSCLC

Sedentary Behaviour, Physical Activity, and Their Associations with Health Outcomes at the Time of Diagnosis in People with Inoperable Lung Cancer

547 CERPASS: A randomized, controlled, open-label, phase 2 study of cemiplimab ± RP1 in patients with advanced cutaneous squamous cell carcinoma

The place of PD-1 inhibitors in melanoma management

Human leucocyte antigen genotype association with the development of immune-related adverse events in patients with non-small cell lung cancer treated with single agent immunotherapy

Optimal management of immune-related toxicities associated with checkpoint inhibitors in lung cancer

Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation

Abstract P066: Prognostic and predictive value of pre-treatment T-Cell receptors (TCR) repertoire in non-small cell lung cancer (NSCLC) patients treated with single agent immunotherapy

Circulating Melanoma Cell Subpopulations: Their Heterogeneity and Differential Responses to Treatment

Clinical evidence for synergy between immunotherapy and radiotherapy (SITAR)

Phase Ib study of olinvacimab (O) with pembrolizumab (P) in patients with recurrent glioblastoma (rGBM)

Powering single-cell genomics to unravel circulating tumour cell subpopulations in non-small cell lung cancer patients

Immune checkpoint inhibitor therapy for advanced cutaneous squamous cell carcinoma in Australia: a retrospective real world cohort study

Brief Report: Real-World Toxicity and Survival of Combination Immunotherapy in Pleural Mesothelioma—RIOMeso

Completion of Pembrolizumab in Advanced Non-Small Cell Lung Cancer—Real World Outcomes After Two Years of Therapy (COPILOT)

Suchergebnisse filtern